Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.01+0.05 (+0.15%)
Close on Nov 17, 2026Market cap $1.92BP/E 10.7Yield –
Harmony Biosciences EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Harmony Biosciences's EV/EBITDA was 6.4× on Nov 11, 2026, against 6.8× a year earlier. Over the last 5 years it ranged from 4.8× to 37.4×, with a median of 8.7×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.4× | −0.9 |
| 2025 | Dec 31, 2025 | 7.3× | −2.6 |
| 2024 | Dec 31, 2024 | 9.9× | +1.3 |
| 2023 | Dec 29, 2023 | 8.6× | −22.5 |
| 2022 | Dec 30, 2022 | 31.1× | −6.3 |
| 2021 | Dec 31, 2021 | 37.4× | – |
See a number that looks wrong?